Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Sources
2.2. Study Population
2.3. Establishment of Predictive Model
2.4. Gene Signature Evaluation
2.5. Statistical Analysis
3. Results
3.1. Construction of the Prediction Model for Disease-Specific Survival
3.2. Development and Validation of a Risk Stratification Model for MAC with Stage II
3.3. Identifying the Differentially Expressed Genes in ArrayExpress Dataset
3.4. KEGG Pathway Analysis and Construction of the PPI Network
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Edge, S.B.; Byrd, D.R.; Carducci, M.A.; Compton, C.C.; Fritz, A.; Greene, F. AJCC Cancer Staging Manual; Springer: New York, NY, USA, 2010; Volume 649. [Google Scholar]
- Luo, C.; Cen, S.; Ding, G.; Wu, W. Mucinous colorectal adenocarcinoma: Clinical pathology and treatment options. Cancer Commun. 2019, 39, 13. [Google Scholar] [CrossRef] [Green Version]
- Dienstmann, R.; Vermeulen, L.; Guinney, J.; Kopetz, S.; Tejpar, S.; Tabernero, J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 2017, 17, 79–92. [Google Scholar] [CrossRef] [PubMed]
- Bosman, F.T.; Carneiro, F.; Hruban, R.H.; Theise, N.D. WHO Classification of Tumours of the Digestive System; World Health Organization: Geneva, Switzerland, 2010. [Google Scholar]
- Verhulst, J.; Ferdinande, L.; Demetter, P.; Ceelen, W. Mucinous subtype as prognostic factor in colorectal cancer: A systematic review and meta-analysis. J. Clin. Pathol. 2012, 65, 381–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, J.S.; Huh, J.W.; Park, Y.A.; Cho, Y.B.; Yun, S.H.; Kim, H.C.; Lee, W.Y.; Chun, H.K. Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine 2015, 94, e658. [Google Scholar] [CrossRef] [PubMed]
- Nitsche, U.; Zimmermann, A.; Späth, C.; Müller, T.; Maak, M.; Schuster, T.; Slotta-Huspenina, J.; Kaser, S.A.; Michalski, C.W.; Janssen, K.P.; et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann. Surg. 2013, 258, 775–782. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamaguchi, T.; Taniguchi, H.; Fujita, S.; Sekine, S.; Yamamoto, S.; Akasu, T.; Kushima, R.; Tani, T.; Moriya, Y.; Shimoda, T. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology 2012, 61, 162–169. [Google Scholar] [CrossRef]
- Yoshioka, Y.; Togashi, Y.; Chikugo, T.; Kogita, A.; Taguri, M.; Terashima, M.; Mizukami, T.; Hayashi, H.; Sakai, K.; de Velasco, M.A.; et al. Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas. Cancer 2015, 121, 4359–4368. [Google Scholar] [CrossRef] [PubMed]
- Ishihara, S.; Watanabe, T.; Akahane, T.; Shimada, R.; Horiuchi, A.; Shibuya, H.; Hayama, T.; Yamada, H.; Nozawa, K.; Matsuda, K.; et al. Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. Int. J. Colorectal Dis. 2012, 27, 371–379. [Google Scholar] [CrossRef]
- Zhang, R.; Zhao, J.; Xu, J.; Chen, Y. Long-term outcomes and prognostic factors of young patients with mucinous and signet-ring cell colorectal cancer. Arch. Med. Sci. 2020, 16, 359–365. [Google Scholar] [CrossRef]
- Chu, K.C.; Miller, B.A.; Feuer, E.J.; Hankey, B.F. A method for partitioning cancer mortality trends by factors associated with diagnosis: An application to female breast cancer. J. Clin. Epidemiol. 1994, 47, 1451–1461. [Google Scholar] [CrossRef]
- Daly, M.C.; Paquette, I.M. Surveillance, epidemiology, and end results (SEER) and SEER-medicare databases: Use in clinical research for improving colorectal cancer outcomes. Clin. Colon Rectal Surg. 2019, 32, 61–68. [Google Scholar] [CrossRef]
- Weiss, J.M.; Pfau, P.R.; O’Connor, E.S.; King, J.; LoConte, N.; Kennedy, G.; Smith, M.A. Mortality by stage for right- versus left-sided colon cancer: Analysis of surveillance, epidemiology, and end results—Medicare data. J. Clin. Oncol. 2011, 29, 4401–4409. [Google Scholar] [CrossRef] [Green Version]
- Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020, 76, 182–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wright, M.N.; Dankowski, T.; Ziegler, A. Unbiased split variable selection for random survival forests using maximally selected rank statistics. Stat. Med. 2017, 36, 1272–1284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Katzman, J.L.; Shaham, U.; Cloninger, A.; Bates, J.; Jiang, T.; Kluger, Y. DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol. 2018, 18, 24. [Google Scholar] [CrossRef]
- Fotso, S.J.a.p.a. Deep neural networks for survival analysis based on a multi-task framework. arXiv 2018, arXiv:1801.05512. [Google Scholar]
- Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3, 1. [Google Scholar] [CrossRef]
- Xia, J.; Gill, E.E.; Hancock, R.E. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat. Protoc. 2015, 10, 823–844. [Google Scholar] [CrossRef]
- Xia, J.; Benner, M.J.; Hancock, R.E. NetworkAnalyst—Integrative approaches for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014, 42, W167–W174. [Google Scholar] [CrossRef] [Green Version]
- Purdie, C.A.; Piris, J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology 2000, 36, 121–126. [Google Scholar] [CrossRef]
- Xie, L.; Villeneuve, P.J.; Shaw, A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: A population-based study in Canada. Int. J. Oncol. 2009, 34, 1109–1115. [Google Scholar] [CrossRef]
- Warschkow, R.; Tarantino, I.; Huttner, F.J.; Schmied, B.M.; Guller, U.; Diener, M.K.; Ulrich, A. Predictive value of mucinous histology in colon cancer: A population-based, propensity score matched analysis. Br. J. Cancer 2016, 114, 1027–1032. [Google Scholar] [CrossRef]
- Catalano, V.; Loupakis, F.; Graziano, F.; Bisonni, R.; Torresi, U.; Vincenzi, B.; Mari, D.; Giordani, P.; Alessandroni, P.; Salvatore, L.; et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann. Oncol. 2012, 23, 135–141. [Google Scholar] [CrossRef]
- Hogan, J.; Burke, J.P.; Samaha, G.; Condon, E.; Waldron, D.; Faul, P.; Coffey, J.C. Overall survival is improved in mucinous adenocarcinoma of the colon. Int. J. Colorectal Dis. 2014, 29, 563–569. [Google Scholar] [CrossRef] [PubMed]
- Kanemitsu, Y.; Kato, T.; Hirai, T.; Yasui, K.; Morimoto, T.; Shimizu, Y.; Kodera, Y.; Yamamura, Y. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis. Colon Rectum 2003, 46, 160–167. [Google Scholar] [CrossRef] [PubMed]
- Kang, H.; O’Connell, J.B.; Maggard, M.A.; Sack, J.; Ko, C.Y. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis. Colon Rectum 2005, 48, 1161–1168. [Google Scholar] [CrossRef]
- Hosseini, S.; Bananzadeh, A.M.; Salek, R.; Zare-Bandamiri, M.; Kermani, A.T.; Mohammadianpanah, M. Prognostic significance of mucinous histologic subtype on oncologic outcomes in patients with colorectal cancer. Ann. Coloproctol. 2017, 33, 57–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347, 1260419. [Google Scholar] [CrossRef]
- Takemasa, I.; Kittaka, N.; Hitora, T.; Watanabe, M.; Matsuo, E.; Mizushima, T.; Ikeda, M.; Yamamoto, H.; Sekimoto, M.; Nishimura, O.; et al. Potential biological insights revealed by an integrated assessment of proteomic and transcriptomic data in human colorectal cancer. Int. J. Oncol. 2012, 40, 551–559. [Google Scholar] [CrossRef]
- Jiang, W.; Li, X.; Rao, S.; Wang, L.; Du, L.; Li, C.; Wu, C.; Wang, H.; Wang, Y.; Yang, B. Constructing disease-specific gene networks using pair-wise relevance metric: Application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements. BMC Syst. Biol. 2008, 2, 72. [Google Scholar] [CrossRef] [Green Version]
- Uemura, M.; Nouso, K.; Kobayashi, Y.; Tanaka, H.; Nakamura, S.; Higashi, T.; Ono, T.; Nakayama, E.; Hanafusa, T.; Shiratori, Y. Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma. Cancer 2003, 97, 2474–2479. [Google Scholar] [CrossRef] [Green Version]
- Kirana, C.; Peng, L.; Miller, R.; Keating, J.P.; Glenn, C.; Shi, H.; Jordan, T.W.; Maddern, G.J.; Stubbs, R.S. Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread. Clin. Proteom. 2019, 16, 3. [Google Scholar] [CrossRef] [Green Version]
- Wen, S.; Wang, X.; Wang, Y.; Shen, J.; Pu, J.; Liang, H.; Chen, C.; Liu, L.; Dai, P. Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells. Artif. Cells Nanomed. Biotechnol. 2018, 46, 896–905. [Google Scholar] [CrossRef] [Green Version]
- Liu, H.; Zhang, Q.; Li, K.; Gong, Z.; Liu, Z.; Xu, Y.; Swaney, M.H.; Xiao, K.; Chen, Y. Prognostic significance of USP33 in advanced colorectal cancer patients: New insights into β-arrestin-dependent ERK signaling. Oncotarget 2016, 7, 81223–81240. [Google Scholar] [CrossRef] [Green Version]
- Ding, C.; Luo, J.; Fan, X.; Li, L.; Li, S.; Wen, K.; Feng, J.; Wu, G. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels. J. Exp. Clin. Cancer Res. 2017, 36, 56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herr, R.; Halbach, S.; Heizmann, M.; Busch, H.; Boerries, M.; Brummer, T. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene 2018, 37, 1576–1593. [Google Scholar] [CrossRef] [PubMed]
- Yu, C.; Hong, H.; Zhang, S.; Zong, Y.; Ma, J.; Lu, A.; Sun, J.; Zheng, M. Identification of key genes and pathways involved in microsatellite instability in colorectal cancer. Mol. Med. Rep. 2019, 19, 2065–2076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsu, C.H.; Hsu, C.W.; Hsueh, C.; Wang, C.L.; Wu, Y.C.; Wu, C.C.; Liu, C.C.; Yu, J.S.; Chang, Y.S.; Yu, C.J. Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteom. 2016, 15, 2396–2410. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Terol, M.; Gazon, H.; Lemasson, I.; Duc-Dodon, M.; Barbeau, B.; Césaire, R.; Mesnard, J.M.; Péloponèse, J.M., Jr. HBZ-mediated shift of JunD from growth suppressor to tumor promoter in leukemic cells by inhibition of ribosomal protein S25 expression. Leukemia 2017, 31, 2235–2243. [Google Scholar] [CrossRef]
- Paulo, P.; Maia, S.; Pinto, C.; Pinto, P.; Monteiro, A.; Peixoto, A.; Teixeira, M.R. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. PLoS Genet. 2018, 14, e1007355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
KERRYPNX | Before Matching | After Matching | ||||
---|---|---|---|---|---|---|
MAC n = 4390 | TAC n = 2704 | p-Value | MAC n = 2618 | TAC n = 2618 | p-Value | |
Age at diagnosis, y, mean (SD) | 69.8 (14.5) | 68.6 (13.9) | <0.001 | 68.8 (14.7) | 68.9 (13.8) | 0.877 |
Sex, n (%) | <0.001 | 0.934 | ||||
Male | 2010 (45.8) | 1326 (49.0) | 1267 (48.4) | 1263 (48.2) | ||
Female | 2380 (54.2) | 1378 (51.0) | 1351 (51.6) | 1355 (51.8) | ||
Tumor grade, n (%) | <0.001 | 0.151 | ||||
Well-differentiated | 522 (11.9) | 341 (12.6) | 335 (12.8) | 326 (12.5) | ||
Moderately-differentiated | 3144 (71.6) | 2105 (77.8) | 2040 (77.9) | 2036 (77.8) | ||
Poorly-differentiated | 615 (14.0) | 213 (7.9) | 217 (8.3) | 211 (8.1) | ||
Undifferentiated | 109 (2.5) | 45 (1.7) | 26 (1.0) | 45 (1.7) | ||
Primary site, n (%) | <0.001 | |||||
Cecum | 1277 (29.1) | 915 (33.8) | ||||
Ascending | 1219 (27.8) | 605 (22.4) | ||||
Hepatic flexure | 302 (6.9) | 141 (5.2) | ||||
Transverse | 531 (12.1) | 252 (9.3) | ||||
Splenic flexure | 155 (3.5) | 99 (3.7) | ||||
Descending | 217 (4.9) | 129 (4.8) | ||||
Sigmoid | 592 (13.5) | 512 (18.9) | ||||
Rectal | 97 (2.2) | 51 (1.9) | ||||
Race, n (%) | <0.001 | 0.917 | ||||
Hispanic (All Races) | 469 (10.7) | 315 (11.6) | 304 (11.6) | 302 (11.5) | ||
Non-Hispanic American Indian/Alaska Native | 12 (0.3) | 10 (0.4) | 8 (0.3) | 7 (0.3) | ||
Non-Hispanic Asian or Pacific Islander | 261 (5.9) | 174 (6.4) | 173 (6.6) | 168 (6.4) | ||
Non-Hispanic Black | 453 (10.3) | 364 (13.5) | 349 (13.3) | 329 (12.6) | ||
Non-Hispanic White | 3195 (72.8) | 1841 (68.1) | 1784 (68.1) | 1812 (69.2) | ||
Tumor depth, n (%) | <0.001 | |||||
T3 | 3604 (82.1) | 2376 (87.9) | ||||
T4 | 786 (17.9) | 328 (12.1) | ||||
Tumor size, mm, mean (SD) | 64.5 (42.4) | 54.0 (47.6) | <0.001 | 54.3 (30.0) | 53.3 (30.4) | 0.211 |
Variables | High Risk | Low Risk | p-Value | |
---|---|---|---|---|
n = 18 | n = 16 | |||
Prognosis, n (%) | ||||
Good prognosis | 5 (27.8) | 13 (72.2) | 0.006 | |
Poor prognosis | 13 (72.2) | 3 (16.7) | ||
Sex, n (%) | ||||
male | 11 (61.1) | 6 (33.3) | 0.303 | |
female | 7 (38.9) | 10 (55.6) | ||
Cancer-related death, n (%) | ||||
Yes | 11 (61.1) | 2 (11.1) | 0.011 | |
No | 7 (38.9) | 14 (77.8) | ||
Tumor grade, n (%) | ||||
Well-differentiated | 1 (5.6) | 2 (11.1) | 0.466 | |
Moderately-differentiated | 12 (66.7) | 11 (61.1) | ||
Poorly-differentiated | 5 (27.8) | 2 (11.1) | ||
Undifferentiated | 0 (0.0) | 1 (5.6) | ||
Lymphovascular invasion, n (%) | ||||
Yes | 5 (27.8) | 2 (11.1) | 0.507 | |
No | 11 (61.1) | 12 (66.7) | ||
N/A | 2 (11.1) | 2 (11.1) | ||
T stage, n (%) | ||||
3 | 13 (72.2) | 16 (88.9) | 0.072 | |
4 | 5 (27.8) | 0 (0.0) | ||
Tumor location, n (%) | ||||
Caecum | 5 (27.8) | 6 (33.3) | ||
Ascending colon | 1 (5.6) | 8 (44.4) | 0.017 | |
Hepatic flexure | 2 (11.1) | 0 (0.0) | ||
Transverse colon | 5 (27.8) | 2 (11.1) | ||
Splenic flexure | 3 (16.7) | 0 (0.0) | ||
Descending colon | 0 (0.0) | 0 (0.0) | ||
Sigmoid colon | 2 (11.1) | 0 (0.0) | ||
Family history of CRC | ||||
Yes | 1 (5.6) | 0 (0.0) | >0.999 | |
No | 10 (55.6) | 6 (33.3) | ||
N/A | 7 (38.9) | 10 (55.6) | ||
Cancer recurrence | ||||
Yes | 14 (77.8) | 3 (16.7) | 0.002 | |
No | 4 (22.2) | 13 (72.2) | ||
Age at diagnosis, y, mean (SD) | 78.33 (8.02) | 70.13 (5.82) | 0.002 | |
Length of follow up, y, mean (SD) | 3.14 (2.16) | 6.01 (2.74) | 0.002 | |
Tumor cell content, (%) | 73.89 (14.61) | 67.19 (16.22) | 0.217 | |
Number of regional LN assessed | 14.5 (8.28) | 17.5 (8.66) | 0.312 | |
Tumor size, cm, mean (SD) | 7.02 (2.41) | 5.28 (1.77) | 0.022 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, C.W.; Cha, J.M.; Kwak, M.S. Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma. Cancers 2021, 13, 3280. https://doi.org/10.3390/cancers13133280
Kim CW, Cha JM, Kwak MS. Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma. Cancers. 2021; 13(13):3280. https://doi.org/10.3390/cancers13133280
Chicago/Turabian StyleKim, Chang Woo, Jae Myung Cha, and Min Seob Kwak. 2021. "Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma" Cancers 13, no. 13: 3280. https://doi.org/10.3390/cancers13133280